SH Business Summary

Senhwa Biosciences (6492.TWO) is a clinical-stage biopharmaceutical company specializing in the development of first-in-class small molecule therapeutics for oncology, infectious diseases, and rare pediatric cancers. The company operates on a high-density R&D model, generating value through strategic licensing agreements, milestone payments, and global research partnerships rather than direct product sales. Its primary business segments are centered on two lead assets: Pidnarulex (CX-5461), a G-quadruplex stabilizer targeting DNA repair-deficient tumors, and Silmitasertib (CX-4945), a selective Casein Kinase 2 (CK2) inhibitor being evaluated for cholangiocarcinoma and HIV functional cures. As of March 2026, Senhwa has expanded its portfolio into photodynamic therapy (PDT) and AI-driven drug optimization through a strategic MOU with CellType. It competes directly with local oncology peers such as OBI Pharma (4174.TWO), Gongwin Biopharm (6617.TWO), and Energenesis Biomedical (6657.TWO), positioning itself as a niche leader in DNA damage response (DDR) and protein kinase inhibition pathways. The company was co-founded by Chairman Benny T. Hu and Dr. Tai-Sen Soong, leveraging deep expertise in venture capital and biotechnology. The current leadership team is headed by Acting CEO and Chief Medical Officer Jason Huang, M.D., a former Janssen (Johnson & Johnson) executive with extensive experience in global clinical operations and therapeutic area expertise. Other key executives include Executive Vice President and CFO Sarah Chang, a CPA with a background in investment trust management, and COO Mei-Hui Kuo, who oversees clinical planning and coordination. The board and investor base feature prominent institutional backing from H&Q Asia Pacific and WI Harper Group, reflecting a pedigree of high-level financial and industrial leadership within the Taiwanese and international biotech ecosystems.